Wnt3a Mitigates Acute Lung Injury by Reducing P2X7 Receptor-Mediated Alveolar Epithelial Type I Cell Death

Y Guo,A Mishra,T Weng,N R Chintagari,Y Wang,C Zhao,C Huang,L Liu
DOI: https://doi.org/10.1038/cddis.2014.254
2014-01-01
Cell Death and Disease
Abstract:Acute lung injury (ALI) is characterized by pulmonary endothelial and epithelial cell damage, and loss of the alveolar–capillary barrier. We have previously shown that P2X7 receptor (P2X7R), a cell death receptor, is specifically expressed in alveolar epithelial type I cells (AEC I). In this study, we hypothesized that P2X7R-mediated purinergic signaling and its interaction with Wnt/ β -catenin signaling contributes to AEC I death. We examined the effect of P2X7R agonist 2′-3′-O-(4-benzoylbenzoyl)-ATP (BzATP) and Wnt agonist Wnt3a on AEC I death in vitro and in vivo . We also assessed the therapeutic potential of Wnt3a in a clinically relevant ALI model of intratracheal lipopolysaccharide (LPS) exposure in ventilated mice. We found that the activation of P2X7R by BzATP caused the death of AEC I by suppressing Wnt/ β -catenin signaling through stimulating glycogen synthase kinase-3 β (GSK-3 β ) and proteasome. On the other hand, the activation of Wnt/ β -catenin signaling by Wnt3a, GSK-3 β inhibitor, or proteasome inhibitor blocked the P2X7R-mediated cell death. More importantly, Wnt3a attenuated the AEC I damage caused by intratracheal instillation of BzATP in rats or LPS in ventilated mice. Our results suggest that Wnt3a overrides the effect of P2X7R on the Wnt/ β -catenin signaling to prevent the AEC I death and restrict the severity of ALI.
What problem does this paper attempt to address?